BridgeBio Pharma, Inc. (BBIO) Stock Overview
Explore BridgeBio Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
BridgeBio Pharma, Inc. (BBIO)
Key Financials
Key Financials
Market Cap
14.2B
P/E Ratio
-20.27
EPS (TTM)
$-3.74
ROE
0.32%
BBIO Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of BridgeBio Pharma, Inc. (NASDAQ: BBIO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, BridgeBio Pharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BBIO on the NASDAQ shows an RSI of 29.51, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $91.08 for the NASDAQ listing.
Key metrics behind BridgeBio Pharma, Inc.'s NASDAQ-traded stock include a P/E ratio of -20.27 and a market capitalization of 14.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BBIO on the NASDAQ.